Venus Remedies Ltd has filed its third PCT International application for an international patent for another of its R&D product in the last month of 2005, under the application titled the "Fixed Dose Combination (FDC) Drug of latest generation Cephalosporin with an Aminoglycoside".

The company's claim for this patent shall get international accreditation once the European Patent Office files its report of international search for this patent application within the next year, being the authorized International Preliminary Examining Authority for this PCT appointed by the company.

This new FDC shall be launched shortly in the domestic markets worth INR 400 crore and expected to be a blockbuster launch, like its predecessors, this Premium Critical Care formulation is projected gain approximately 10 per cent market share within one year of its launch in its segment.

The Company is launching this product under Strategic Marketing Tie-ups with some of the prominent names in Indian Pharmaceutical Industry to ensure its proper placement in its respective segment. This PCI application shall help to gain international credibility for this new Product and be a launch pad for launching this product globally in a market worth US $ 1 billion.

Negotiations are underway with some MNCs for launching this Premium Critical Care Product in overseas market.